AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05228873 — intervention group
Intervention type: DRUG
Intervention: Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng)
Description: Patients take Shen Cao Gan Jiang Tang (Gan Cao Gan Jiang Tang with Ginseng), one bag of decoction (90ml) two times a day for 10 days. Ingredients per formula (tang): 12 grams of honey-fried Radix Glycyrrhizae, 6 grams of Rhizoma Zingiberis (stir-baked), 6 grams of Panax Ginseng. The decoction of concentrated extract is packed into aluminum foil vacuum bag, 90ml per bag, 1 formula (tang) is equivalent to 2 bags. Patients use the decoction directly from the bag.
Study NCT04515602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary debulking surgery
Description: Primary debulking surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5.
Study NCT04515602 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neoadjuvant chemotherapy
Description: 3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy.
Study NCT04515602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARPi
Description: For patients with gBRCA/sBRCA mutation and CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors.
Study NCT04515602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PARPi
Description: For patients with gBRCA/sBRCA mutation and CR/PR after first-line chemotherapy, maintenance therapy of PARP inhibitors.
Study NCT06122038 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rice power placebo. Dispensed during visit 1. Participants will consume 1 dose per day for 10 days.
Study NCT04941261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine
Description: Intramuscular injection of middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm
Study NCT04941261 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine
Description: Intramuscular injection of high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine in the deltoid muscle of the upper arm
Study NCT04941261 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intramuscular injection of placebo in the deltoid muscle of the upper arm
Study NCT05505006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose Injection
Description: Anemic patients with ID will receive i.v. iron. Dosage will be based on Hb level and patient body weight.
Study NCT05505006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Anemic patients with folate deficiency will receive folic acid 5 mg per day for 1 month
Study NCT05505006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B12
Description: Anemic patients with B12 deficiency will receive B vitamin complex 1 tablet per day for 1 month
Study NCT05350852 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ThisCART19A
Description: ThisCART19A is a new type CAR-T cells therapy for patients with acute B-cell leukemia
Study NCT06473792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotic Toothpaste
Description: Composition: Main - Water, calcium carbonate, calcium glycerophosphate, glycerin, xylitol, sodium bicarbonate, sweet fennel oil (Foeniculum vulgare), carrageenan, maltodextrin, Dental-Lac (Lactobacillus paracasei), potassium sorbate, yucca (Y. filamentosa) powder, stevia leaf extract (Eupatorium rebaudiana bertoni), zinc chloride.~Usage: This is mint flavored toothpaste containing Lactobacillus paracasei which has demonstrated the ability to help address harmful strains of oral flora, and promotes the maintenance of a healthy teeth and gums. The participant will be instructed to brush with it twice daily.
Study NCT04983355 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Hydrolysate
Description: The participants take 4 capsules/day of the study product. Two capsules should be consumed orally every morning with breakfast and/or with a glass of (plain, not sparkling) water and not with fruit juice or hot food/drink while ingesting the capsules; and two capsules should be consumed orally every evening with their dinner and/or with a glass of water.~Participants receiving the fish hydrolysate the fourth first weeks will then receive the placebo during another 4 weeks. A wash-out period of 4 weeks is included between each phase of supplementation.
Study NCT04983355 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants take 4 capsules/day of the study product. Two capsules should be consumed orally every morning with breakfast and/or with a glass of (plain, not sparkling) water and not with fruit juice or hot food/drink while ingesting the capsules; and two capsules should be consumed orally every evening with their dinner and/or with a glass of water.~Participants receiving the Placebo the fourth first weeks will then receive the fish hydrolysate during another 4 weeks. A wash-out period of 4 weeks is included between each phase of supplementation.
Study NCT05541575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR films
Description: A new virtual reality course for home care workers to experience the view of dementia people with BPSD and the relative feelings.
Study NCT05348200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monad 1
Description: Single therapy cream containing Lidocaine. Lidocaine is a topical anesthetic.
Study NCT05348200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monad 2
Description: Single therapy cream containing Halobetasol Propionate (low-strength). HPB is a topical corticosteroid.
Study NCT05348200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monad 3
Description: Single therapy cream containing Halobetasol Propionate (high strength).
Study NCT05348200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination - CITI-002 (low dose)
Description: Combination cream containing Lidocaine and HBP (low)
Study NCT05348200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination - CITI-002 (high dose)
Description: Combination cream containing Lidocaine and HBP (high)
Study NCT06291558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The first 5 minutes of heating in the exercise program are planned to be implemented for 8 weeks, and the last 5 minutes are a cooling period. In the exercise program, which is planned to last 40 minutes in total, respiratory exercises will be applied to heating and cooling peryotes. As respiratory exercise, diaphragmatic respiratory exercise will be applied to heating and cooling peryots with 5 repetitions. Elastic resistant bands (Therand) will be used in resistant exercise training that will last for 30 minutes. The participants will be started to work with the resistance that they can do 10 again but cannot reach 14 repetitions. Elastic resistant bands are shoulder flexion, shoulder extension, shoulder ablution, shoulder horizontal abduction, elbow extension, hip ablution, hip flexion, and hip exercise. These exercises will be held once a week, 10 repetitions, 2 sets, for 8 weeks.
Study NCT06190561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07940367
Description: Participants to receive a single dose of PF-07940367 product II 150 mg by mouth
Study NCT06020703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fermented Food Diet
Description: Subjects will incorporate 1 serving of fermented food a day and increase to 6 more each day as tolerated for 4 weeks. After the initial 4 weeks, subjects will eat 6 or more servings of fermented foods each day for 8 weeks.
Study NCT06190561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07940367
Description: Participants to receive a single dose of PF-07940367 product I 150 mg by mouth
Study NCT06207526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blended face-to-face and smartphone intervention
Description: The intervention comprises two phases: an initial stage involves baseline assessment, in-depth app training, psychoeducation, and EMA monitoring for functional analysis. The subsequent phase focuses on identifying and implementing individual coping strategies, forming the basis for daily personalized EMI reminders. Over six days, participants receive ten daily surveys to gauge fluctuations in paranoia and delusional ideation. EMA-derived feedback, considering antecedents and coping responses, shapes a personalized EMI. Four sessions with a psychologist involve discussing app feedback, emphasizing functional analysis, coding coping strategies into the app, assessing utility, and adapting as needed. Post-session two, five coping reminders and an eight-item evening survey are sent daily for two blocks of ten days to monitor delusional ideations and coping strategy effectiveness.
Study NCT05899738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Specified dose on specified days
Study NCT05467501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theraputic ultrasound
Description: Therapeutic ultrasound
Study NCT05467501 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Theraputic ultrasound
Description: Therapeutic ultrasound
Study NCT05489367 — intervention group
Intervention type: BIOLOGICAL
Intervention: sars cov 2 biontec vaccine
Description: volunteers will be expected to receive 2 doses of vaccine
Study NCT05747703 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ria Treatment Platform
Description: combined medication, coaching, education, and monitoring
Study NCT05373849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: essentiel oil mixtures in inhaler sticks (step 1) - no intervention (step 2)
Description: The participant will receive the study treatment (essential oils mixture in inhaler sticks for 2 months) and the control (no intervention for 2 months). At inclusion and at the end of each period, questionnaires of well-being, anxiety and stress will be completed
Study NCT05373849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: no intervention (step 1) - essential oils mixture in inhaler sticks (step 2)
Description: The participant will receive the control (no intervention for 2 months) and the study treatment (essential oils mixture in inhaler sticks for 2 months). At inclusion and at the end of each period, questionnaires of well-being, anxiety and stress will be completed.
Study NCT06174610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of Renal Resistive Index
Description: The kidneys are preliminarily visualized in a 2D projection, followed by identifying interlobar or arcuate vessels using color Doppler. Flow measurements in these vessels are performed using pulsed-wave Doppler. Renal Resistive Index is determined over three cardiac cycles (five in the case of atrial fibrillation) in two different arteries, each in a different kidney section. Subsequently, measurements from each artery are averaged. If possible, the examination should be conducted bilaterally.~The investigators do not have access to previous measurements (each study is recorded on a separate card).
Study NCT05641415 — intervention group
Intervention type: OTHER
Intervention: Imaging
Description: MRI and x-ray of both shoulders
Study NCT05888987 — intervention group
Intervention type: BIOLOGICAL
Intervention: PCR multiplex by FilmArray
Description: PCR multiplex by FilmArray system on corneal swabbing sample
Study NCT05326867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration of 2% Lidocaine with Needle
Description: Infiltration of 2% Lidocaine with Needle
Study NCT05326867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infiltration of 2% Lidocaine without Needle
Description: Free needle infiltration of lidocaine can be an alternative to reduce epidural needle insertion pain. The study of Gozdemir et al. found that 10% lidocaine infiltration without needle was less painful than 2% lidocaine infiltration with a 27G needle with no significant difference in analgesia effect during epidural needle insertion. This study aimed to compare infiltration of lidocaine with and without needle for epidural needle insertion
Study NCT06576401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] HDM1002
Description: Administered orally
Study NCT06380075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectralis FAF imaging
Description: Spectralis is a scanning laser ophthalmoscope which uses a blue light excitation wavelength of 488nm and a 500nm barrier filter to produce FAF images. Spectralis images 20-55 degrees of the retina.
Study NCT06380075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optos imaging
Description: Optos is an ultrawide field imaging platform which images up to 200 degrees of the retina. It uses both a green-light excitation wavelength of 532nm and a red-light excitation wavelength of 633nm with an emission filter of greater than 540nm to produce FAF images.
Study NCT06380075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clarus imaging
Description: Clarus 700 is an ultrawide field imaging system with similar retinal coverage to that of Optos. It uses Broad Line Fundus Imaging to produce blue FAF images at excitation wavelengths of 435-500nm and green FAF images at wavelengths of 500-585nm
Study NCT05145868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol Skills and Emotion Regulation Intervention
Description: The text-based intervention will provide alcohol reduction strategies and emotion regulation skills.
Study NCT05145868 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Text-messages will be sent that include no intervention content to serve as an attention control
Study NCT06725290 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ocular Surface Disease Index (OSDI) questionnaire
Description: The OSDI is a validated, self-administered questionnaire for assessing the presence and severity of ocular surface disease symptoms. The OSDI questionnaire includes 12 questions about the respondent's past week experience with the ocular symptoms, vision-related function, and environmental triggers
Study NCT06726876 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Manuka honey oral rinse.
Description: Name: Manuka Honey Oral Rinse~Description:~Dosage: Patients will use 20 ml of Manuka honey diluted in 100 ml of purified water.~Administration: Oral rinse, performed 3 times per day.~Instructions: Patients are instructed to rinse their mouths with the solution for a specified duration and avoid swallowing it.~Unique Elements:~Active Ingredient: Manuka honey, known for its unique antibacterial properties due to high levels of methylglyoxal (MGO).~Mechanism of Action: MGO and Non-Peroxide Activity (NPA) contribute to antibacterial potency, effective against antibiotic-resistant bacteria, and potential immunomodulatory effects that aid wound healing and tissue regeneration.~Additional Procedures: Scaling and root debridement, along with the local application of 0.5 ml non-diluted Thyme honey on sites with Probing Pocket Depth (PPD) ≥ 5 mm.~Supplementary Care: Patients receive motivation and detailed oral hygiene instructions (proper tooth brushing technique, flossing, use of inte
Study NCT06726876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline rinses.
Description: Dosage: Patients will use 20 ml of normal saline.~Administration: Oral rinse, performed 3 times per day.~Instructions: Patients are instructed to rinse their mouths with the saline solution for a specified duration and avoid swallowing it.~Unique Elements:~Control Comparison: Provides a placebo comparison to evaluate the efficacy of the Manuka honey intervention.~Additional Procedures: Scaling and root debridement, along with the local application of 0.5 ml non-diluted Thyme honey on sites with Probing Pocket Depth (PPD) ≥ 5 mm.
Study NCT06010511 — intervention group
Intervention type: OTHER
Intervention: 3T MRI scan
Description: Conventional (3T) brain MRI scans will be used to determine global and functional markers of cerebral SVD, like WMH volume and presence of lacunes, microbleeds and superficial siderosis (3D T1, 3D FLAIR, SWI, DWI), hemodynamics (arterial spin labelling \& flow territory mapping) and white matter structural integrity (diffusion tensor imaging (DTI)). Furthermore, we want to measure structural integrity with a novel MR fingerprinting sequence and an inhomogeneous magnetization transfer (ihMT) MRI scan. We also want to apply a fMRI scan technique to measure CSF fluctuations in the 4th ventricle as a measure of brain glymphatics. Also the flow-territory mapping sequence is a non-standard sequence. Heart rate and respiratory signal will be measured during the scans (3T and 7T MRI) with standard vendor-supplied equipment.
Study NCT06010511 — intervention group
Intervention type: OTHER
Intervention: 7T MRI scan
Description: Ultra-high field (7T) brain MRI scans will be used to determine WMH shape and other markers of cerebral SVD in or surrounding the WMH, like local enlarged perivascular spaces, (cortical) microinfarcts and microbleeds (T1, T2, FLAIR and T2\*) and vascular pulsatility (phase contrast MRI). Moreover, a recently implemented MRI technique to measure glymphatic flow in perivascular spaces will be used.
Study NCT06010511 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neuropsychological assessment
Description: * Mini-mental state examination~* Clock drawing~* 15-Word Verbal Learning Test, immediate and delayed~* Visual Association Test~* Stroop Color Word Test, 40 item version~* Trail Making Test A\&B~* Letter Digit Substitution Test~* Animal fluency test~* Hospital anxiety and depression scale~* Informant Questionnaire on Cognitive Decline in the Elderly
Study NCT06010511 — intervention group
Intervention type: OTHER
Intervention: General baseline data
Description: Baseline data, such as age, sex, psychiatric comorbidity and medication lists will be extracted from the patient files.~Age (Year of birth); Years of education; BMI (height \& weight); Sex; Verhage scale (education); Smoking status; Blood values; Sleep habits; Waste-hip ratio; Blood pressure; Current/general cardiovascular health; Psychiatric comorbidity; medical history related to cardiovascular health.
Study NCT06345573 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mental stress
Description: Two consecutive validated mental stress tests, namely 1) the Montreal Imaging Stress Task consisting of two series of 15-minute mental calculation tests, without (Control Mode) and with (Stress Mode) negative feedback, respectively; and 2) the Trier Social Stress Test consisting of a 5-minute mock job interview (Speech Part) followed by a 5-minute mental calculation test (Mental Arithmetic Part).
Study NCT05795127 — intervention group
Intervention type: PROCEDURE
Intervention: First metatarsophalangeal joint arthrodesis
Description: Surgery leadin to bony uninon in firts metatarsophalangeal joint
Study NCT04856852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iodine-125+Chemotherapy
Description: Iodine-125: Iodine-125 if necessary, 0.6-0.8mCi, PD:120-150Gy Temozolomide: 75 mg per square meter of body-surface area per day, 7 days per week,42 days.
Study NCT06100913 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)
Description: The study vaccine is an FDA-approved recombinant vesicular stomatitis virus (rVSV) expressing the envelope glycoprotein of Ebola virus Zaire (rVSV∆G-ZEBOV-GP). The dose of rVSV∆G-ZEBOV-GP vaccine has been chosen for this study as per package insert recommendations and based on clinical data. Participants receive 1.0 milliliter (mL) of the study vaccine administered intramuscularly in the deltoid muscle of the non-dominant arm.
Study NCT04856852 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical resection+Radiochemotherapy
Description: Surgical resection: Maximal surgical resection, including gross total resection, subtotal resection, and partial resection.~Radiation: total 60 Gy, 2 Gy per daily fraction (Monday to Friday) for 6 weeks. Temozolomide: 75 mg per square meter of body-surface area per day, 7 days per week,42 days.
Study NCT05345301 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Event related desynchronization measurement
Description: Individuals will spend one hour and receive cues to open or close their hand while wearing a EEG cap and EMG sensors on their forearm.
Study NCT04770948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 19 gauge needle
Description: EBUS-TBNA performed using 19G needle
Study NCT04770948 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22 gauge needle
Description: EBUS-TBNA performed using 22G needle
Study NCT04717817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) using an IMT Threshold device (Philips)
Description: Inspiratory muscle training on a daily basis prior to surgery during 2-3 weeks
Study NCT04717817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physiotherapy
Description: Standard instructions and physiotherapy prior to surgery during 2-3 weeks
Study NCT03867643 — intervention group
Intervention type: BIOLOGICAL
Intervention: hepatitis B vaccine(HepB)
Description: Children with anti-HBs at a low level (\<10mIU/mL and \[10,100) mIU/mL) were received a dose of hepatitis B vaccine booster after informed consent.